An objective source
of truth for
hair-loss progress.
Tuesday night, 10 PM. Michael squints at two scalp photos a month apart — different lighting, slightly off angle — unable to tell if anything has changed. He repeats this every two weeks, unsure the $1,500/year is working.A composite self-researcher
Self-researchers on long-term treatments track progress with inconsistent phone photos — different lighting and angles make real change impossible to judge.
A clinical-grade progress journal — the objective source of truth for treatment efficacy, beyond generic AI photo comparison.
SCAN said Caution (6); the deep pass held it — confirmed the pain and sharpened the ICP.
The path is sharp; differentiation vs free alternatives is the open question.
Will users pay for tracking on top of expensive treatments, versus 'good enough' free phone photos?
Clinical-grade journal
A trusted source of truth for treatment efficacy — beyond commoditized AI photo comparison, winning on trust and data integrity.
Reddit r/tressless
A high-density, high-intent community where the ICP actively discusses treatments, frustrations, and tracking methods.
$25 Founder's Circle
A pre-order (first year 50% off) — the smallest transaction that validates true purchase intent, not just verbal interest.
Send 50 personalized outreach messages to active r/tressless users posting about tracking or treatment frustration.
- Pass if
- 10+ discovery calls booked.
- If fail
- Re-work messaging or test another hair-loss forum.
Show a 2-min Loom demo of the photo-capture + comparison workflow to 8+ prospects.
- Pass if
- 5+ say “I need this” or articulate why it beats their phone.
- If fail
- Value prop isn’t differentiated — revisit the workflow.
Drive 100+ targeted visitors to a landing page with the $25 ‘Founder’s Circle’ pre-order.
- Pass if
- 5+ paid pre-orders.
- If fail
- Interest ≠ willingness-to-pay — pivot the offer or pricing.
Digitally-savvy individuals actively undergoing — and financially invested in — long-term hair-loss treatments (minoxidil, finasteride, post-transplant), frustrated by unreliable, inconsistent self-tracking. The pain is emotional, frequent, and tied to real money spent.
“I can’t tell if this treatment is even working.”
“Every photo looks different — I can’t compare them.”
“I spend $1,500 a year with no proof it helps.”
“My doctor barely tracks it; I feel unheard.”
“I wish I could show my dermatologist real data.”
Competitors all compete on AI photo analysis — a sea of sameness. The real unserved pain is trust: users don't believe their own inconsistent photos, so they can't tell whether expensive treatments work. Winning means being the objective source of truth, not another AI gimmick.
Early-adopter self-researchers on long-term treatment, frustrated by inconsistent self-tracking.
"Stop guessing if your hair-loss treatment is working — get objective, visual proof of progress."
Michael Lee
"Serious money in — my phone photos aren't cutting it."
Sarah Jenkins
"Can't tell if I'm holding steady. I need hard data."
David Chen
"I need to track every follicle's progress."
Positioning carves out trust and data integrity instead of fighting in the crowded AI-photo-analysis space — reframing the category from 'AI gimmick' to a clinical-grade progress journal that serious users, and their doctors, can rely on.
Objective proof, not a gut feeling — measure what your treatment is actually doing.
A clinical-grade journal you and your dermatologist can both trust.
Beyond generic AI photo comparison — consistency and data integrity first.
Objective source of truth ★
The clinician bridge
The motivation engine
Obtainable over 3 years — Y1 $68K · Y2 $206K · Y3 $481K (1% → 3% → 7% of SOM)
The TAM is large, but the realistic obtainable market is a focused $6.9M — rescoped from a broad $32.8M to the ICP beachhead. A viable niche, not a billion-dollar opportunity for this product alone. The key risk: willingness to pay on top of treatment costs, versus free phone photos.
Recommended model: Freemium + subscription. Free tier (basic photo journal); premium at $7–$15/mo unlocks AI density/thickness analysis, trend charts, and clinician-shareable reports. Lowers the barrier for self-funded users and tests willingness-to-pay directly.
| Assumption | What the CFO flagged | Before → after | Sev |
|---|---|---|---|
| CAC | Sub-$50 assumes community channels carry it; paid D2C health typically runs 2–3× higher. | <$50→$75 | High |
| Monthly churn | Natural drop-off once users conclude their treatment is or isn't working; 3% understates it and inflates LTV. | 3%→5.5% | High |
| Compliance | Dated scalp photos tied to a person are health-adjacent PII — GDPR + SOC 2 readiness isn't in the model. | $0→$5–15k/yr | Med |
| Break-even | Recomputed from the corrected CAC and churn above — the bar to clear moves up. | 667→~900 | — |
- Compliance: confirm the $5–15k/yr GDPR + SOC 2 line.
- Channel: no paid-vs-organic CAC benchmark yet.
- Conversion: the free→paid uplift is unproven in-category.
- Retention: do users stay past the "verdict moment"?
- ~80% gross margin, realistic once ~$3/mo cloud + AI cost is counted.
- Freemium is the correct wedge for testing willingness-to-pay.
- Pricing anchored to the $30–100+/mo users already spend.
- 3:1 LTV:CAC is the right sustainability bar to hold.
Doctor-ready progress report
The app becomes a clinical communication tool: a premium feature generates a structured, shareable report for the user's dermatologist — a defensible B2C2B bridge.
Clinical adherence tool (B2B)
Pivot B2C→B2B: sell SaaS to clinics and dermatologists to monitor patient progress, improve adherence, and prove value — reducing churn.
Post-transplant recovery tracker
Narrow to the highest-stakes niche: post-transplant patients tracking graft healing, density, and shed/regrowth through the critical 12-month recovery.
- Tell me about your hair-loss treatment journey so far.
- What prompted your current regimen?
- How long have you been treating it?
- Walk me through the last time you tried to assess if it was working.
- What made comparing progress over time hard?
- How often do you try to track changes?
- What do you wish you could consistently monitor?
- A time you felt uncertain or frustrated about effectiveness?
- What do you spend today on tools to understand progress?
- What time / emotional energy goes into tracking?
- How did you decide a past health tool was worth it?
- What objective data would justify the investment, given treatment costs?
- How often are you frustrated/uncertain it's working? (frequency)
- Which methods do you use to track today? (behavior)
- Which tracking challenges do you hit? (pain)
- How appealing is a dedicated tracking platform? (solution fit)
- How likely would you be to use it? (intent)
- Reasonable monthly price? (WTP)
- Problem severity > 3.5 / 5
- Current-method satisfaction < 3 / 5
- Purchase intent ≥ 30% likely
- Willingness to pay $7/mo ≥ 40%
A Go needs problem severity, low current satisfaction, solution fit, and purchase intent all clearing their bars.
The pain is validated and the ICP is reachable. What gates a build is differentiation + willingness-to-pay — proof that users will pay for tracking on top of treatment costs, versus free phone photos. Run the 90-day plan; if it validates, proceed to BUILD. If not, the 'Doctor-Ready Progress Report' pivot is the fastest fallback into a defensible B2C2B moat.
Biggest risk: a direct incumbent (Hairly, MyHair.ai) or a telehealth giant (Hims, Ro) adds richer outcome tracking before differentiation is established.
Escalate to BUILD
Once the 90-day plan validates the core problem, BUILD adds:
- · MVP definition
- · RICE backlog
- · User flows
- · Screen specs
- · Architecture
- · 30-day sprint